Pfizer’s Omnitrope Options Include Approval Challenge, Substitutability Fight
Executive Summary
Pfizer's response to the approval of Sandoz' Omnitrope could signal the extent to which industry gauges the legality of approving follow-on biologics under the 505(b)(2) pathway
You may also be interested in...
FDA Review Of Follow-On Biologics Would Put Brands, Generics Under One Roof
The pending legislation to create a pathway for approval of follow-on biologics would also create a new organizational template for review of generic products
FDA Review Of Follow-On Biologics Would Put Brands, Generics Under One Roof
The pending legislation to create a pathway for approval of follow-on biologics would also create a new organizational template for review of generic products
Scientific, Not Legal, Developments Are Key To Generic Biologics – McClellan
Generic drug firms can speed creation of a pathway for generic biologics by focusing on the science behind the products, former FDA commissioner Mark McClellan said